Clinical Analgesic Management in Dementia

Inclusion Criteria: * Male or female, aged 50 to 90 years at the time of enrollment. * Meets the NIA-AA core clinical diagnostic criteria for probable Alzheimer's disease. * Clinical Dementia Rating - Global Score (CDR-GS) between 0.5 and 2.0, inclusive, and Clinical Dementia Rating - Memory Box (CDR-MB) score ≥ 0.5. * Diagnosed with chronic pain within 6 months prior to enrollment and considered appropriate for opioid therapy. * Presence and severity of pain confirmed using PAINAD, MOBID-2, or comparable scales. * Educational attainment: at least 4-6 years of formal education, or not illiterate. * If currently receiving psychotropic or cognitive-enhancing medications, the dosage must have been stable for at least 3 months prior to study entry and remain unchanged during the study. Unless otherwise specified, all other permitted concomitant medications (non-AD related) must be stably administered for at least 4 weeks prior to baseline. * Has a reliable caregiver/companion who can assist with study participation, defined as a person who can support the participant throughout the study and spend at least 8 hours per week with the participant. * Willing and able to participate in this clinical trial, to maintain the assigned intervention during the study period, and has signed the informed consent form. Exclusion Criteria: * History of transient ischemic attack (TIA), stroke, or seizure within the past 12 months. * Presence of any psychiatric diagnosis or symptoms that may in…